FORM PTO-1449					INT'L FILING NO.		PCT/EP2	PCT/EP2004/013248	
INFORMATION DISCLOSURE STATEMENT					INT'L FILING DATE		Novemb	November 19, 2004	
					APPLICANT		Jean-Ch	Jean-Christophe	
								BARLAND	
					GROUP				
					EXAMINER				
				ATTORNEY DOCKET NO.			PB60595	SUSw	
U.S. PATENT DOCUMENTS									
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate	
	1.	6,342,496	1/29/2002	Jerussi et	t al.				
	2.	6,337,328	1/8/2002	Fang et al.					
	3.	6,391,875	5/21/2002	Morgan et al.					
	4.	6,274,579	8/14/2001	Morgan et al.					
	5.	2002/052340	5/2/2002	Jerussi et al.					
	6.	2002/052341	5/2/2002	Fang et a	ıl.				
	7.	2003/064988	4/3/2003	Morgan e					
	8.	2003/032643	2/13/2003	Ascher et al.					
	9.	2003/083330	5/1/2003	Partridge					
	10.	2003/027827	2/6/2003	Broom et al.					
	FOREIGN PATENT DOCUMENTS  Document Publication Translation								
		Document Number	Publication		Country	Class	Subclass	Yes   No	
	11.	WO 01/62257	8/30/2001	PCT		Class	Subciass	•	
				PCT					
	12.	WO 00/51546	9/8/2000						
	13.	WO 99/37305	7/29/1999	PCT					
	14.	1336406	8/20/2003	EP					
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
	15.	ASCHER et al., Burpropion: A Review of its Mechanics and Antidepressent Activity, J. Clinical Psychiatry <b>56</b> :395-401 (1985)							
	16.	ALLEN and EARLEY, Restless Legs Syndrome, J. of Clinical Neurophysiology <b>18(2)</b> :128-147 (2001).							
	17.	ALLEN et al., Restless legs syndrome: diagnotistic criteria, special considerations, and epidemiology, Sleep Medicine <b>4</b> :101-119 (2003).							
	18.	CHESSON et al., Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic							
	10.	Limb Movement Disorder, Sleep <b>22(7)</b> :961-968 (1999).							
	19.	EARLEY, Restless Legs Syndrome, The New England Journal of Medicine, <b>348(21)</b> :2103-2109							
		(2003).							
	20.	KELLEY et al., (2S,3S,5R)-2-(3,5-Difluorophenyl)-3,5-dimethyl-2-morpholinol: A Novel							
		Antidepressant Agent and Selective Inhibitor of Norepinephrine Uptake, J. Med. Chem <b>39</b> :347-349 (1996).							
	21.	NOFZINGER et al., Bupropion SR Reduces Periodic Limb Movements Associated with Arousals							
	21.	from Sleep in Depressed Patients with Periodic Limb Movement Disoder, J. Clin Psychiatry							
	61:858-862 (2000).							rino and	
	22.	STAHL et al., A Review of the Neuropharmacology of Bupropion, A Dual Norepinephrine and Dopamine Reuptake Inhibitor, Prim Care Companion J. Clin Psychiatry <b>6(4)</b> :159-166 (2004).							
	22								
	23.	STIASNY et al., Restless Legs Syndrome and its Treatment by dopamine agonists, Parkinsonism and Related Disorders <b>7</b> :21-25 (2001).							
_	24.	WALTERS, Toward a Better Definition of the Restless Legs Syndrome, Movement Disorder <b>10</b> :634-642 (1995).							
		10.034-042 (18)							
EXAMINER		<u> </u>					CONSIDERE	:D	
							CONGIDENC		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.